APLS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Apellis is not a good new buy right now for a Beginner long-term investor with $50,000-$100,000 to deploy. The stock is already effectively tied to Biogen’s $41 cash acquisition value, and the current price around 41 leaves very little upside from here. Since the investor is impatient and does not want to wait for a better entry, the better choice is to avoid initiating a fresh position now and simply hold if already owned. The situation is more of a merger-arbitrage hold than a compelling long-term buy.
APLS is trading essentially at the deal price and in a tight range around the pivot at 41.007, with support at 40.915 and resistance at 41.099. The moving averages are bullish in structure (SMA_5 > SMA_20 > SMA_200), but momentum is not convincing because MACD is negative at -0.727 and the histogram is still below zero. RSI_6 at 72.964 suggests the stock is near overbought territory despite being labeled neutral in the data. Overall, the chart looks flat and capped near the acquisition price rather than showing a fresh upside trend.
["Biogen announced a $41.00 per share cash acquisition of Apellis, creating a clear near-term price floor near the deal value.", "Shareholders may also receive two contingent payments of $2.00 each if Syfovre sales thresholds are met.", "Revenue in Q1 2026 rose 15.12% YoY to 192.01M, showing continued top-line growth.", "Hedge funds are buying, with holdings increasing 132.99% over the last quarter."]
["Upside is limited because the stock is already trading essentially at the acquisition price.", "Multiple analysts downgraded the stock to Neutral/Hold/Equal Weight after the deal announcement, signaling reduced fundamental upside.", "MACD remains negative and momentum is weak despite bullish moving averages.", "The stock trend model points to negative expected returns over the next day, week, and month.", "Insiders are neutral, with no meaningful recent buying signal.", "No AI Stock Picker or SwingMax signal is present today."]
In Q1 2026, Apellis delivered revenue of 192.01M, up 15.12% YoY, which is a positive growth trend. However, profitability weakened materially: net income fell to 0, EPS dropped to 0.15 from higher levels last year, and gross margin slipped slightly to 78.88%. The latest quarter season is Q1 2026, and the financial picture shows sales growth but weaker earnings quality.
Recent analyst activity has shifted decisively to the sidelines after Biogen’s acquisition announcement. JPMorgan, Jefferies, Stifel, William Blair, Roth, H.C. Wainwright, and Mizuho all moved to Neutral/Hold/Market Perform-type views with $41 targets, while Wells Fargo downgraded to Equal Weight and RBC raised its target to $41 but kept Sector Perform. The Wall Street pros view is mostly that the deal is fair and near full value, with little room for further appreciation. In short, analysts largely see Apellis as priced for the takeover rather than as a fresh long-term upside idea.
